Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
The new project further expands the partner's long-term collaboration on new technologies for R&D
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Post the sale, Patel family has become the single largest promoter shareholder in the company
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
This partnership stemmed from a successful customer-supplier relationship spanning several years.
New Lexington, Massachusetts facility to provide customer education and collaboration opportunities
Subscribe To Our Newsletter & Stay Updated